FN2 Earnings Intelligence
The Mosaic Company earnings overview
Latest The Mosaic Company (MOS) earnings intelligence, including the newest scorecard, market reaction, and transcript analysis.
The Mosaic Company
Mosaic's near-term phosphate business remains pressured by sulfur costs, supply constraints and potentially lower application rates. Cost reductions, disciplined capital spending, growing Mosaic Biosciences revenue and lower potash costs provide support, but the evidence is mixed rather than uniformly positive.
The Mosaic Company
Mosaic's Q1 FY2026 was defined by a severe EPS miss ($0.05 vs $0.24 estimated) as soaring sulfur and ammonia prices forced temporary phosphate production curtailments. Revenue of $3.0B slightly exceeded consensus. Management responded by cutting 2026 capex by $250M to $1.25B and launching a $50M cost-savings program. The potash segment stayed resilient on record Canpotex sales and strong Asian demand. Management tone shifted from confident in Q4 to cautious, with the bullish score falling from 70 to 45. Long-term growth drivers -- Mosaic Biosciences expansion and a new rare-earth extraction partnership with Rainbow Rare Earths -- remain intact but are not near-term catalysts. The stock declined 1.80% on the report with 2.06x baseline volume and continued to drift lower.
The Mosaic Company
Mosaic's maintained 2026 framework and operating-efficiency initiatives support a constructive longer-term setup, but the evidence is mixed: sulfur costs, demand softness, capital intensity, and execution risks still need to ease for the improvement case to gain credibility.
The Mosaic Company
The current analysis supports a constructive but conditional view: improving asset reliability, resilient potash demand, cost savings, and expanding biologicals could support earnings progress, while cash conversion, phosphate execution, and Brazil-related risks limit confidence.
The Mosaic Company
The supplied analysis supports a constructive but execution-dependent view: improved operations, tighter fertilizer markets, Brazil expansion, Biosciences growth, and cost reductions provide support, while commodity, credit, weather, tariff, and turnaround risks remain material.
The Mosaic Company
The supplied analysis supports a constructive but conditional view: resilient fertilizer pricing, Brazilian execution, new capacity and Biosciences growth support the operating case, while cost control, working capital, maintenance and global supply risks must be monitored.
The Mosaic Company
The supplied analysis supports a cautiously constructive Mosaic operating outlook: strong fertilizer margins, tight phosphate supply, cost reduction, and project execution are positives, but production turnarounds, foreign exchange, tariffs, geopolitics, and Brazil credit risk remain material offsets.
Get the MOS recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.